ISRCTN16270186进行中（未招募）未知
Safety and immunogenicity extension study for ChAdOx1 nCoV-19
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 1,077
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Participated in the COV001 - Phase I/II or COV002 - Phase II/III trials
- •2. Able and willing to provide written, informed consent to participate in the study
- •3. Able and willing (in the investigator’s opinion), to comply with all study requirements
- •4. Consent to general practitioner or responsible physician being notified of participation in the study
- •5. Consent to allow investigators to discuss their medical information with their general practitioner (GP) or responsible physician, and to access any medical records where relevant to the study
- •6. Consent to access NHS SARS-CoV-2 NAAT results, including viral sequencing, results from NHS Digital and local sequencing labs, as well as COVID-19 vaccination records if available
排除标准
- •1. Participants who have enrolled on a clinical trial of an investigational medicinal product (CTIMP) for a novel COVID-19 vaccine will be excluded. Examples would include the COV-Variant or ComCOV trials
- •2. Participants who fail to enrol onto COV009 within 26 weeks of their last study visit on the parent study will be excluded. If consent is not obtained within 26 days from the last visit on the parent trial, the participant will become ineligible for COV009
研究者
相似试验
招募中
不适用
Effects of Covieshield vaccine on Liver cirrhosis patientsCTRI/2021/03/032158Institute of Liver and Biliary Sciences
尚未招募
3 期
A Partially-Blinded, Randomized, Phase 3 Study to Evaluate the Immunogenicity and Safety of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Healthy Adults and Individuals with HIV Infectiosevere acute respiratory syndrome coronavirus 2 SARS CoV 2PACTR202108616900606Clover Biopharmaceuticals AUS Pty Ltd600
尚未招募
Unknown
Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in MozambiquePoliovirusPACTR202404654347323World Health Organization888
已完成
3 期
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in IndiaCTRI/2010/091/000020Sanofi Pasteur SA100
进行中（未招募）
1 期
Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated poliomyelitis vaccine (DT Polio®) when given as a booster dose at 6 years of age - REVAXIS® versus DT Polio® as a second booster in 6 year-old childreot applicable - Healthy volunteers - 6 year-old childEUCTR2005-001446-16-FRSanofi Pasteur MSD760